$SMMT Ivonescimab Plus Chemotherapy Demonstrates OS Superiority Compared to Durvalumab Plus Chemo in Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study. #ESMO26

Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 25% Compared to Durvalumab Plus Chemotherapy; OS Hazard Ratio 0.75
https://www.businesswire.com/news/home/20261025603151/en/Ivonescimab-Plus-Chemotherapy-Demonstrates-Overall-Survival-Superiority-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Treatment-of-Patients-with-Advanced-Biliary-Tract-Cancer-in-HARMONi-GI1-Study-Conducted-by-Akeso-in-China